Phase III trial shows ultra-low-dose nivolumab improves overall survival in pretreated solid tumors, suggesting better dosing strategies.
Ultra-low-dose nivolumab significantly improves OS versus chemotherapy in pretreated solid tumors, with fewer severe toxicities and better QoL. These findings support re-evaluation of ICI dosing strategies and may enhance global access.
No takes yet. Share an insight, caveat, or question.
Noronha et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: